Browsing by Author "Kilickap, Saadettin"
Now showing items 1-20 of 34
-
Antibody responses to COVID-19 vaccination in cancer: a systematic review
Guven, Deniz Can; Sahin, Taha Koray; Kilickap, Saadettin; Uckun, Fatih M. (Frontiers Media SA, 2021)Introduction: After the results of phase III vaccine studies became available, the leading oncology societies recommended two doses of COVID-19 vaccination to all patients with cancer with no specific recommendation for ... -
The association between albumin-globulin ratio (AGR) and survival in patients treated with immune checkpoint inhibitors
Guven, Deniz Can; Aktepe, Oktay Halit; Aksun, Melek Seren; Sahin , Taha Koray; Kavgaci, Gozde; Ucgul, Enes; Cakir, Ibrahim Yahya; Yildirim, Hasan Cagri; Guner, Gurkan; Akin, Serkan; Kertmen, Neyran; Dizdar, Omer; Aksoy, Sercan; Erman, Mustafa; Suayib, Yalcin; Kilickap, Saadettin (IOS Press, 2022)BACKGROUND: The albumin-globulin ratio (AGR) could be a prognostic biomarker in patients with cancer, although the data is limited in patients treated with immune-checkpoint inhibitors (ICIs). OBJECTIVES: We aimed to ... -
The association between antibiotic use and survival in renal cell carcinoma patients treated with immunotherapy: a multi-center study
Guven, Deniz Can; Acar, Ramazan; Yekedüz, Emre; Bilgetekin, İrem; Baytemur, Naziyet Kose; Erol, Cihan; Ceylan, Furkan Sacit; Kılıçkap, Saadettin (Mosby Inc., 2021)Background: Immunotherapy improves overall survival (OS) in the second and later lines of renal cell carcinoma (RCC) treatment. Recent studies have suggested that antibiotic (ATB) use either shortly before or after the ... -
The association between early changes in neutrophil-lymphocyte ratio and survival in patients treated with immunotherapy
Guven, Deniz Can; Sahin, Taha Koray; Erul, Enes; Cakir, Ibrahim Yahya; Ucgul, Enes; Yildirim, Hasan Cagri; Aktepe, Oktay Halit; Erman, Mustafa; Kilickap, Saadettin; Aksoy, Sercan; Yalcin, Suayib (MDPI, 2022)Dynamic changes in the blood-based biomarkers could be used as a prognostic biomarker in patients treated with immune checkpoint inhibitors (ICIs), although the data are limited. We evaluated the association between the ... -
The Association between the Pan-Immune-Inflammation Value and Cancer Prognosis: A systematic review and meta-analysis
Guven, Deniz Can; Sahin, Taha Koray; Erul, Enes; Kilickap, Saadettin; Gambichler, Thilo; Aksoy, Sercan (PMC, 2022)Background: Prognostic scores derived from the blood count have garnered significant interest as an indirect measure of the inflammatory pressure in cancer. The recently developed pan-immune-inflammation value (PIV), an ... -
The association of BMI and sarcopenia with survival in patients with glioblastoma multiforme
Güven, Deniz Can; Aksun, Melek Seren; Çakır, İbrahim Yahya; Kılıçkap, Saadettin; Kertmen, Neyran (2021)Background: The association between obesity and sarcopenia (via temporal muscle thickness) with overall survival (OS) has been evaluated in several glioblastoma multiforme studies, however, the data are inconclusive. ... -
Atezolizumab combined with chemotherapy in the first-line treatment of extensive-stage small cell lung cancer: A real-life data of the Turkish Oncology Group
Gurbuz, Mustafa; Kutlu, Yasin; Akkus, Erman; Koksoy, Elif Berna; Kose, Naziyet; Oven, Bala Basak; Uluc, Basak Oyan; Demiray, Atike Gokcen; Erdem, Dilek; Demir, Bilgin; Turhal, Nazım Serdar; Uskent, Necdet; Akbas, Sinem; Selcukbiricik, Fatih; Inal, Ali; Bilici, Ahmet; Kilickap, Saadettin (Springer, 2022)Purpose Atezolizumab has been shown to be efective and safe in randomized trial in the frst-line treatment of extensivestage small cell lung cancer (SCLC). However, there are limited real-life data on atezolizumab. In this ... -
The benefit of treatment beyond progression with immune checkpoint inhibitors: A multi-center retrospective cohort study
Guven, Deniz Can; Yekeduz, Emre; Erul, Enes; Coskun Yazgan, Sati; Sahin, Taha Koray; Karatas, Gokturk; Aksoy, Sercan; Erman, Mustafa; Yalcin, Suayib; Urun, Yuksel; Kilickap, Saadettin (Springer, 2022)Objective: Treatment beyond progression (TBP) with immune checkpoint inhibitors (ICIs) is an evolving field due to the limitations of conventional imaging in response evaluation. However, real-life data on the benefit of ... -
Blood based biomarkers as predictive factors for hyperprogressive disease
Yildirim, Hasan Cagri; Guven, Deniz Can; Aktepe, Oktay Halit; Taban, Hakan; Yilmaz, Feride; Yasar, Serkan; Aksoy, Sercan; Erman, Mustafa; Kilickap, Saadettin; Yalcin, Suayib (MDPI, 2022)Purpose: With the widespread use of immunotherapy agents, we encounter treatment responses such as hyperprogression disease (HPD) that we have not seen with previous standard chemotherapy and targeted therapies. It is known ... -
Clinical outcomes of concomitant use of proton pump inhibitors and regorafenib in patients with metastatic colorectal cancer: A multicenter study
Yekeduz, Emre; Ozbay, Mehmet Fatih; Caglayan, Dilek; Yildirim, Atila; Erol, Cihan; Yildirim, Hasan Cagri; Tunc, Sezai; Ozyurt, Neslihan; Ozdemir, Feyyaz; Sendur, Mehmet Ali Nahit; Kilickap, Saadettin (LIPPINCOTT WILLIAMS & WILKINS, 2022)Clinical outcomes of concomitant use of proton pump inhibitors and regorafenib in patients with metastatic colorectal cancer: A multicenter study -
Clinical outcomes of concomitant use of proton pump inhibitors and regorafenib in patients with metastatic colorectal cancer: a multicenter study
Yekeduz, Emre; Ozbay, Mehmet Fatih; Caglayan, Dilek; Yildirim, Atila; Erol, Cihan (SPRINGER, 2022)Aim To compare survival outcomes, response rates, and adverse events (AEs) in proton pump inhibitor (PPI) user and nonuser patients with metastatic colorectal cancer (mCRC) treated with regorafenib. Methods We included ... -
Clinical outcomes of cyclin-dependent kinase 4–6 (CDK 4–6) inhibitors in patients with male breast cancer: a multicenter study
Yildirim, Hasan Cagri; Mutlu, Emel; Chalabiyev, Elvin; Ozen, Mirac; Keskinkilic, Merve (Churchill Livingstone, 2022)Background: Since breast cancer is less common in men than in women, data on the use of new therapeutic agents, including cyclin-dependent kinase 4–6 (CDK 4–6) inhibitors, are limited in patients with metastatic hormone ... -
Crizotinib efficacy after progression with entrectinib in ROS1-Positive lung cancer: a case report
Taban, Hakan; Guven, Deniz Can; Kilickap, Saadettin (CUREUS INC, 2022)Crizotinib and entrectinib are approved tyrosine kinase inhibitors by the FDA to treat advanced-stage ROS1-positive non-small cell lung cancer (NSCLC). Although, entrectinib could be used after crizotinib, it is unknown ... -
Crizotinib efficacy and safety in patients with advanced NSCLC harboring MET alterations: a real-life data of Turkish oncology group
Gürbüz, Mustafa; Bilici, Ahmet; Karadurmuş, Nuri; Sezer, Ahmet; Şendur, Mehmet Ali Nahit; Paydaş, Semra; Artaç, Mehmet; Fulden Yumuk, Perran; Gürsoy, Pinar; Uysal, Mükremin; Şenol Coşkun, Hasan; Kilickap, Saadettin (Lippincott Williams and Wilkins, 2022)Crizotinib is a multikinase inhibitor, effective in non-small cell lung cancer (NSCLC) harboring mesenchymal-epidermal transition (MET) alterations. Although small prospective studies showed efficacy and safety of crizotinib ... -
Differences between hyperprogressive disease and progressive disease in patients receiving immunotherapy
Yildirim, Hasan Cagri; Guven, Deniz Can; Aktepe, Oktay Halit; Taban, Hakan; Yilmaz, Feride; Yasar, Serkan; Aktas, Burak Yasin; Guner, Gurkan; Dizdar, Omer; Aksoy, Sercan; Erman, Mustafa; Yalcin, Suayib; Kilickap, Saadettin (Kare Publishing, 2022)Objectives: Although immune checkpoint inhibitors (ICIs) became a vital part of cancer care, many patients do not respond to treatment. In this group, a few of the patients with a hyperprogressive disease (HPD) have shorter ... -
Differences between hyperprogressive disease and progressive disease in patients receiving immunotherapy
Yildirim, H. C.; Guven, D. C. C.; Aktepe, O. H.; Yilmaz, F.; Aktas, B. Y.; Guner, G.; Dizdar, O.; Aksoy, S.; Erman, M.; Yalcin, S.; Kilickap, Saadettin (ELSEVIER, 2022)Differences between hyperprogressive disease and progressive disease in patients receiving immunotherapy -
External Validation of a Novel Risk Model in Patients With Favorable Risk Renal Cell Carcinoma Defined by International Metastatic Renal Cell Carcinoma Database Consortium (IMDC): Results From the Turkish Oncology Group Kidney Cancer Consortium (TKCC) Database
Yekeduz, Emre; Karakaya, Serdar; Erturk, Ismail; Tural, Deniz; Ucar, Gokhan; Oztas, Nihan Senturk; Ozguroglu, Mustafa; Kucukarda, Ahmet; Sever, Ozlem Nuray; Kilickap, Saadettin; Oksuzoglu, Berna; Demirci, Umut; Arikan, Nuriye (Elsevier, 2022)Background: A novel prognostic model was recommended for patients with metastatic RCC (mRCC) by the International mRCC Database Consortium (IMDC). In this study, we aimed to externally validate a novel risk model for the ... -
First-line treatment of patients with HER2-positive metastatic gastric and gastroesophageal junction cancer
Akturk Esen, Selin; Ergun, Yakup; Erol, Cihan; Arikan, Rukiye; Er, Muhammed Muhiddin (Association of Basic Medical Sciences of FBIH, 2022)Fluoropyrimidine+cisplatin/oxaliplatin+trastuzumab therapy is recommended for the first-line treatment of human epidermal growth factor receptor 2 (HER2)-positive metastatic gastric adenocarcinoma. However, there is no ... -
The health impact projection model of the PD-1/PD-L1 inhibitor class in cancer care in Turkey
Akpamuk, U.; Hughes, R.; Swales, O.; Oyan, B.; Kilickap, S.; Demirci, U. (ELSEVIER SCIENCE INC, 2022)No Abstract Available.
